RxDoctor Payments Data

Ronald Fiore, MD

Neurology · New Orleans, LANPI 1548205362

Payments from drug & device makers

$11,516in general payments, 2019–2025

Across 769 payments — averaging $14.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$922
  • Acadia Pharmaceuticals Inc$871
  • Eisai Inc.$858
  • Teva Pharmaceuticals USA, Inc.$628
  • Pfizer$586
  • plus $6K from 40 others

What the payments were for

  • Speaking & faculty fees$170%
  • Food & beverage$11,10996%
  • Education$3913%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,516 in reported general payments places this provider in the 70th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana

Medicare billing

Part B allowed, 2024
$163,188
Medicare patients
410
Services billed
8,791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5076$960,940
Gamunex-CImmune Globul G/Gly/Iga Avg 4625$394,096
NuplazidPimavanserin Tartrate79$390,319
OctagamImmun Globg(Igg)/Malt/Iga Ov5017$377,631
RytaryCarbidopa/Levodopa136$155,934
AustedoDeutetrabenazine12$152,789
GocovriAmantadine Hcl17$71,148
FycompaPerampanel50$64,554
Nurtec OdtRimegepant Sulfate32$42,847
Emgality PenGalcanezumab-Gnlm57$40,124
Aimovig AutoinjectorErenumab-Aooe40$33,262
UbrelvyUbrogepant28$32,708
QuliptaAtogepant27$30,053
AptiomEslicarbazepine Acetate18$21,649
Oxtellar XrOxcarbazepine11$14,406

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$70$960,94076 claims
PfizerOctagam, Nurtec Odt, Premarin$586$423,20963 claims
Grifols USA, LLCGamunex-C$409$394,09625 claims
Acadia Pharmaceuticals IncNuplazid$871$390,31979 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$199$158,812171 claims
Teva Pharmaceuticals USA, Inc.Austedo$628$152,78912 claims
AbbVieUbrelvy, Qulipta, Namzaric$2,063$71,29569 claims
MDD US Operations, LLCGocovri$459$71,14817 claims
Eisai Inc.Fycompa$858$64,55450 claims
Sunovion Pharmaceuticals Inc.Aptiom$268$21,64918 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$270$14,40611 claims
Axsome Therapeutics, Inc.Sunosi$78$10,02112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 225 neurology providers in Louisiana.

Other neurology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →